SecBot SecBot
Biotech Drug Report Generated Aug 20, 2026

frunexian

CVKD·Cadrenal Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 2-ready (trial not yet initiated; no frunexian trial found in available ClinicalTrials.gov data)
Time to market
Unknown, Phase 2 has not started; if a trial began today, any approval would still be multiple years away, and the company is actively seeking a partner to take the asset forward.
Why 2/10
No hard, dated catalyst exists for frunexian in the next ~12 months: it is 'Phase 2-ready' with no registered trial, no readout, and no PDUFA date in any available source, the only pipeline-wide event (a July 2026 partnering process) is undated and company-wide, not a frunexian binary.
Actionable Insight NEUTRAL

Frunexian alone is not a tradeable binary, it has no scheduled catalyst, no trial data, and an undisclosed mechanism, so any near-term CVKD move is driven by the company-wide partnering process and financing events, not by this drug. Watch for an Item 1.01 8-K announcing a definitive deal or a new Phase 2 registration on ClinicalTrials.gov; treat the ~$14 mean price target (3 analysts, ~690% implied upside) skeptically, and expect dilution risk given the ~33%-dilutive July placement, effective S-3 shelf, and insider selling.

Price Chart

Loading chart...

Executive Summary

Frunexian is Cadrenal Therapeutics' (Nasdaq: CVKD) 'Phase 2-ready' pre-operative safety candidate, the least-advanced of three pipeline assets (alongside CAD-1005, Phase 3-ready for heparin-induced thrombocytopenia, and tecarfarin, Phase 3-ready in orphan indications) at a ~$6M market-cap company with no revenue and no approved products. On July 21, 2026, Cadrenal announced a strategic realignment into a Cardiac Acute Critical Care Franchise and a formal partnering process to out-license or co-develop frunexian and its other late-stage assets, but disclosed no binding agreements or financial terms.

How It Works

Cadrenal positions frunexian as a drug to protect patients around the time of cardiac surgery (its 'Pre-Operative Safety' pillar) within a franchise aimed at life-threatening blood-clotting and immune conditions. The specific mechanism is not described in any source available this session, the '-exian' name suffix hints at an anticoagulant class, but that is not confirmed in the data.

Trial Status

Per Cadrenal's July 21, 2026 8-K, frunexian is one of three late-stage assets in the company's 'Cardiac Acute Critical Care Franchise,' positioned in the 'Pre-Operative Safety' pillar and described as 'Phase 2-ready.' No frunexian-specific clinical trial record, FDA action, or catalyst exists in the local ClinicalTrials.gov/FDA datasets, and the company has initiated a formal process to out-license, monetize, or co-develop it along with CAD-1005 and tecarfarin.

The Two-Sided Case

▲ Bull Case4
Partnering optionality: the July 21, 2026 8-K formally opens an out-licensing/monetization/co-development process for frunexian and its sibling assets, a potential non-dilutive deal for a company with ~$6M market cap (exact snapshot: $6,476,057) and no current revenue.
Analyst support: local consensus shows buy 5 / hold 1 / strongBuy 2 (no sells), and a 3-analyst price-target snapshot shows targetMean $14 (high $17, low $12) against a ~$1.65 stock, with implied upside of 690.3% in the local snapshot (its stored currentPrice was $1.87).
Phase 2-ready positioning gives frunexian a distinct niche, pre-operative safety in cardiac surgery, separate from the HIT (CAD-1005) and orphan (tecarfarin) programs, adding portfolio optionality to the franchise pitch.
Some tracked institutions accumulated in 2026-Q2 data (UBS Group doubled, Morgan Stanley doubled, BlackRock added), per the local 13F-derived evidence.
▼ Bear Case5
No data, no trial, no catalyst: frunexian has no registered clinical trial, no efficacy/safety data, and its mechanism is not described in available sources, it is entirely unproven, and a Phase 2-start is undated.
Severe financing constraints: Cadrenal has no revenue or approved products, and in July 2026 it raised $3M via an H.C. Wainwright private placement of 960,000 shares plus warrants (potentially ~$5.8M more), estimated to dilute ~33%, extending cash runway only into Q1 2027; an S-3 shelf (File No. 333-297432) became effective July 20, 2026, adding dilution overhang.
Insider selling and a locally computed bearish evidence checklist: CEO/Chairman Pham Quang X sold shares repeatedly May–June 2026 under a 10b5-1 plan, and the 90-day bull/bear tool returned netSignal 'bearish' (insider sells, multiple institutional near-exits/trims, and one high short-volume-ratio session at 0.536).
The partnering process is speculative: no binding agreement or financial terms exist, and failure to land a deal would likely be read negatively given the explicit monetization strategy.
Coverage is thin and possibly conflicted: the price-target/consensus comes from just 3 analysts, H.C. Wainwright's accuracy on this name is 'below average' (50 on the local scale), and Wainwright both maintains Buy and placed the dilutive July offering.

Upcoming Catalysts

  • Any definitive partnering / out-licensing agreement for frunexian or the franchise (would come via a material agreement 8-K, undated)
  • Initiation of a Phase 2 trial for frunexian (undated; not yet registered in available ClinicalTrials.gov data)
  • Potential capital raise or shelf takedown under the effective S-3 registration (dilution event)
  • Quarterly financial results and any pipeline updates from Cadrenal

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Cadrenal Therapeutics, Inc. 8-K CVKD ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov7 sec.gov